We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Buy Huntsman (HUN) Stock Right Now
Read MoreHide Full Article
Huntsman Corporation (HUN - Free Report) is gaining from actions to grow its downstream businesses and synergies of acquisitions. We are positive on the company’s prospects and believe that the time is right for you to add the stock to the portfolio as it looks promising and is poised to carry the momentum ahead.
Huntsman currently carries a Zacks Rank #1 (Strong Buy) and a VGM Score of B. Our research shows that stocks with a VGM Score of A or B, combined with a Zacks Rank #1 or 2 (Buy), offer the best investment opportunities for investors.
Let's see what makes this chemical maker an intriguing investment option at the moment.
Price Performance
Huntsman’s shares have gained 27.4% over the past year, outperforming its industry’s decline of 8.5% over the same time frame.
Image Source: Zacks Investment Research
Estimates Northbound
Over the past two months, the Zacks Consensus Estimate for Huntsman for 2022 has increased around 8.8%. The consensus estimate for second-quarter 2022 has also been revised 13.1% upward over the same time frame. The favorable estimate revisions instill investor confidence in the stock.
Healthy Growth Prospects
The Zacks Consensus Estimate for 2022 earnings of $4.34 for Huntsman suggests year-over-year growth of 22.6%. Moreover, earnings are expected to register a 30.2% growth in the second quarter.
Positive Earnings Surprise History
Huntsman has outpaced the Zacks Consensus Estimate in each of the trailing four quarters. In this time frame, it has delivered an earnings surprise of 12.6%, on average.
Growth Drivers in Place
Huntsman remains focused on growing its downstream specialty and formulation businesses and is shifting its MDI (methylene diphenyl diisocyanate) business from components to differentiated systems that typically have higher margins and lower volatility.
The company's Polyurethanes segment is well positioned for strong upside in the long term on the back of its focus on ramping up its high-value differentiated downstream portfolio. Substitution of MDI for less effective materials will remain a key driving factor for the MDI business. Huntsman expects to complete the Geismar MDI splitter project in June 2022, which will expand the differentiated Polyurethanes business in the Americas.
Huntsman should also gain from significant synergies of acquisitions. Its strong liquidity and balance sheet leverage gives it adequate flexibility to continue to develop and expand its core businesses through acquisitions and internal investments. The recent acquisitions of CVC Thermoset and Gabriel Performance Products are significantly contributing to EBITDA in the Advanced Materials segment.
The company expects to deliver around $240 million of annualized cost optimization and acquisition run rate synergies by the end of 2023. It expects to achieve acquisitions-related run rate synergies of roughly $55 million by first-quarter 2023.
Other top-ranked stocks worth considering in the basic materials space include Nutrien Ltd. (NTR - Free Report) , Albemarle Corporation (ALB - Free Report) and Cabot Corporation (CBT - Free Report) .
Nutrien, sporting a Zacks Rank #1, has an expected earnings growth rate of 161.9% for the current year. The Zacks Consensus Estimate for NTR's current-year earnings has been revised 26.9% upward over the last 60 days. You can see the complete list of today’s Zacks #1 Rank stocks here.
Nutrien beat the Zacks Consensus Estimate for earnings in three of the last four quarters while missed once. It has a trailing four-quarter earnings surprise of roughly 5.8%, on average. NTR has rallied 54% in a year.
Albemarle has a projected earnings growth rate of 190.6% for the current year. The Zacks Consensus Estimate for ALB’s current-year earnings has been revised 96.3% upward in the past 60 days.
Albemarle’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average being 22.5%. ALB has rallied roughly 53% in a year. The company flaunts a Zacks Rank #1.
Cabot, currently sporting a Zacks Rank #1, has an expected earnings growth rate of 21.5% for the current fiscal year. The Zacks Consensus Estimate for CBT's earnings for the current fiscal has been revised 5.2% upward in the past 60 days.
Cabot’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average being 16.2%. CBT has gained around 14% over a year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why You Should Buy Huntsman (HUN) Stock Right Now
Huntsman Corporation (HUN - Free Report) is gaining from actions to grow its downstream businesses and synergies of acquisitions. We are positive on the company’s prospects and believe that the time is right for you to add the stock to the portfolio as it looks promising and is poised to carry the momentum ahead.
Huntsman currently carries a Zacks Rank #1 (Strong Buy) and a VGM Score of B. Our research shows that stocks with a VGM Score of A or B, combined with a Zacks Rank #1 or 2 (Buy), offer the best investment opportunities for investors.
Let's see what makes this chemical maker an intriguing investment option at the moment.
Price Performance
Huntsman’s shares have gained 27.4% over the past year, outperforming its industry’s decline of 8.5% over the same time frame.
Image Source: Zacks Investment Research
Estimates Northbound
Over the past two months, the Zacks Consensus Estimate for Huntsman for 2022 has increased around 8.8%. The consensus estimate for second-quarter 2022 has also been revised 13.1% upward over the same time frame. The favorable estimate revisions instill investor confidence in the stock.
Healthy Growth Prospects
The Zacks Consensus Estimate for 2022 earnings of $4.34 for Huntsman suggests year-over-year growth of 22.6%. Moreover, earnings are expected to register a 30.2% growth in the second quarter.
Positive Earnings Surprise History
Huntsman has outpaced the Zacks Consensus Estimate in each of the trailing four quarters. In this time frame, it has delivered an earnings surprise of 12.6%, on average.
Growth Drivers in Place
Huntsman remains focused on growing its downstream specialty and formulation businesses and is shifting its MDI (methylene diphenyl diisocyanate) business from components to differentiated systems that typically have higher margins and lower volatility.
The company's Polyurethanes segment is well positioned for strong upside in the long term on the back of its focus on ramping up its high-value differentiated downstream portfolio. Substitution of MDI for less effective materials will remain a key driving factor for the MDI business. Huntsman expects to complete the Geismar MDI splitter project in June 2022, which will expand the differentiated Polyurethanes business in the Americas.
Huntsman should also gain from significant synergies of acquisitions. Its strong liquidity and balance sheet leverage gives it adequate flexibility to continue to develop and expand its core businesses through acquisitions and internal investments. The recent acquisitions of CVC Thermoset and Gabriel Performance Products are significantly contributing to EBITDA in the Advanced Materials segment.
The company expects to deliver around $240 million of annualized cost optimization and acquisition run rate synergies by the end of 2023. It expects to achieve acquisitions-related run rate synergies of roughly $55 million by first-quarter 2023.
Huntsman Corporation Price and Consensus
Huntsman Corporation price-consensus-chart | Huntsman Corporation Quote
Stocks to Consider
Other top-ranked stocks worth considering in the basic materials space include Nutrien Ltd. (NTR - Free Report) , Albemarle Corporation (ALB - Free Report) and Cabot Corporation (CBT - Free Report) .
Nutrien, sporting a Zacks Rank #1, has an expected earnings growth rate of 161.9% for the current year. The Zacks Consensus Estimate for NTR's current-year earnings has been revised 26.9% upward over the last 60 days. You can see the complete list of today’s Zacks #1 Rank stocks here.
Nutrien beat the Zacks Consensus Estimate for earnings in three of the last four quarters while missed once. It has a trailing four-quarter earnings surprise of roughly 5.8%, on average. NTR has rallied 54% in a year.
Albemarle has a projected earnings growth rate of 190.6% for the current year. The Zacks Consensus Estimate for ALB’s current-year earnings has been revised 96.3% upward in the past 60 days.
Albemarle’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average being 22.5%. ALB has rallied roughly 53% in a year. The company flaunts a Zacks Rank #1.
Cabot, currently sporting a Zacks Rank #1, has an expected earnings growth rate of 21.5% for the current fiscal year. The Zacks Consensus Estimate for CBT's earnings for the current fiscal has been revised 5.2% upward in the past 60 days.
Cabot’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average being 16.2%. CBT has gained around 14% over a year.